DJIA 17,039.49 0.00 0.00%
NASDAQ 4,532.10 0.00 0.00%
S&P 500 1,992.37 0.00 0.00%
market minute promo

Prosensa Holding B.V. (NASDAQ: RNA)

9.06 0.00 (0.00%)

Quote as of

company name or ticker

Recent Quotes

RNA $9.06 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $9.39
Previous Close $9.06
Daily Range $8.94 - $9.50
52-Week Range $3.43 - $26.00
Market Cap $325.6M
P/E Ratio 0.00
Dividend (Yield) $0.00 (0.0%)
Volume 75,154
Average Daily Volume 141,235
Current FY EPS -$0.69



Prosensa Holding B.V. (RNA) Description

Prosensa Holding B.V. Website:

News & Commentary

3 Stocks Crushed by the Market This Week

These health-care stocks experienced a horrendous week -- with each plunging more than 20%.

Prosensa Holding's (RNA) CEO Hans Schikan on Q2 2014 Results - Earnings Call Transcript

Should You Buy Prosensa Holding (RNA) Ahead of Earnings? - Tale of the Tape

Should You Buy Prosensa Holding (RNA) Ahead of Earnings? - Tale of the Tape

3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP

3 Reasons Not to Worry About Sarepta Therapeutics Inc.

Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.

Should Sarepta's Shares Be Tumbling?

Sarepta has updated data from eteplirsen's trial in Duchenne's muscular dystrophy, potentially positioning it to compete against Prosensa's drisapersen and PTC Therapeutics Translarna.

Down 17%: Is Sarepta a Bad News Buy?

Sarepta Therapeutics is down over 20% today on disappointing clinical trial news. Here's what you need to know.

Latest Sarepta Study Update Shows Greater Decline in Walking Ability

Sarepta's Monday Selloff on New (Old) Worries Addressed

Monday Sector Laggards: Drugs, Education & Training Services

See More RNA News...